title: Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.
abstract: The metabolic and hemostatic effects of two oral contraceptives containing 150 mcg desogestrel and 20 mcg ethinyl-estradiol (EE) (MERCILON) or 30 mcg EE (MARVELON) were compared in order to examine the effect of reducing the EE dose in contraceptive pills. Forty-nine women participated in this randomized study during 6 cycles. In both groups, there was a significant increase in triglycerides, HDL-cholesterol and apoprotein A1; the same increase was observed for SBP and CBG. Slight and transient variations of fasting blood glucose levels were seen in the 30 mcg EE group and in the two groups for fasting insulin levels. The increase in renin substrate was significantly higher with the 30 mcg EE than with the 20 mcg EE pill. In both groups, plasminogen increased significantly, but antithrombin III, total and free protein S and fibrinogen decreased significantly only in women taking the 30 mcg EE pill, whereas there was no significant change in the 20 mcg EE group. Reducing the dose of EE in oral contraceptives from 30 mcg to 20 mcg minimizes their impact on renin substrate and hemostatic parameters.
authors.affiliation: Department of Internal Medicine and Nutrition, Hôtel Dieu, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Basdevant
authors.forename: J
authors.initials: J
authors.lastname: Conard
authors.forename: C
authors.initials: C
authors.lastname: Pelissier
authors.forename: T T
authors.initials: TT
authors.lastname: Guyene
authors.forename: C
authors.initials: C
authors.lastname: Lapousterle
authors.forename: M
authors.initials: M
authors.lastname: Mayer
authors.forename: B
authors.initials: B
authors.lastname: Guy-Grand
authors.forename: H
authors.initials: H
authors.lastname: Degrelle
mesh_terms: D016632:Apolipoprotein A-I / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage* / Q000494:pharmacology; D017135:Desogestrel / Q000008:administration & dosage* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D010197:Pancuronium / Q000031:analogs & derivatives* / Q000494:pharmacology; D010958:Plasminogen / Q000378:metabolism; D011446:Prospective Studies; D011486:Protein C / Q000378:metabolism; D017293:Protein S / Q000097:blood; D012083:Renin / Q000097:blood; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D014156:Transcortin / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D003278:Contraceptives, Oral, Hormonal; D011486:Protein C; D017293:Protein S; D012738:Sex Hormone-Binding Globulin; D014280:Triglycerides; D004997:Ethinyl Estradiol; D017135:Desogestrel; D010958:Plasminogen; D014156:Transcortin; D012083:Renin; D010197:Pancuronium; C003549:dacuronium